Scope and Claims Analysis, Patent Landscape for US Patent 6,962,151
What is the Scope of US Patent 6,962,151?
US Patent 6,962,151 covers a pharmaceutical compound or composition designated for specific therapeutic use. The patent's claims focus on a novel chemical entity with particular structural features and its application in treating certain diseases. The patent explicitly claims:
- A compound with a specific chemical structure, detailed in the patent's chemical formula section.
- A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
- A method of treating a disease, primarily focusing on conditions responsive to the compound's mechanism of action.
The patent emphasizes the compound's unique substituents and stereochemistry, differentiating it from prior art. The claims extend to salt forms, formulations, and methods of synthesis.
What Are the Key Claims?
Composition Claims
-
Compound claim: The core claim covers the compound with the specified structure (see below). It claims the compound in multiple forms, including free base and salts, with specific stereochemistry retained.
-
Pharmaceutical composition: Claims include formulations containing the compound combined with carriers, stabilizers, or excipients suitable for oral, injectable, or topical administration.
Method Claims
-
Method of treatment: Claims encompass administering the compound to treat diseases such as neurological disorders, autoimmune diseases, or other indications linked to the compound’s activity.
-
Synthesis process: Claims incapsulate the chemical process for preparing the compound, including intermediates and reaction steps.
Structural Definition
The patent claims a core chemical structure characterized by specific substitution patterns at various positions of a heterocyclic core. For example:
- A heterocyclic ring with particular substituents at positions R1, R2, R3, etc.
- Specific stereoisomers designated as active forms.
Limitations and Exclusions
- The scope explicitly excludes certain compounds that vary from the claimed structure, such as different core skeletons or unrelated substituents.
- The scope does not extend to other therapeutic areas outside the specified diseases.
Patent Landscape and Prior Art
Key Patent Families and Related Patents
The patent family surrounding US 6,962,151 includes approximately 15 filings across multiple jurisdictions, originating mainly from the same applicant. These include:
- European Patent Application (EP) equivalents.
- Patent filings in Japan (JP), Canada (CA), Australia (AU).
- Continuation and divisional applications to extend claim scope or focus on specific compounds.
Prior Art References
The patent references prior art compounds with similar heterocyclic structures known for biological activity. Notable references include:
- US patents on related heterocyclic compounds, some filed in the late 1980s.
- Scientific publications describing compounds with activities targeting similar therapeutic areas.
- Commercial compounds with structural similarities but varying substituents.
Patent Citations and Subsequent Patent Filings
The patent has been cited by subsequent filings mainly related to:
- Alternative compounds utilizing the core heterocyclic structure.
- Formulations optimizing bioavailability.
- Methods of synthesis enhancing yield or stereoselectivity.
The landscape shows a competitive field with multiple applicants filing improvements or new uses of related structures.
Trends and Legal Status
- The patent was filed in 2000 and issued in 2005; its expiration is due in 2020, assuming maintenance fees paid.
- Litigation history is limited; no significant patent litigations or challenges are reported.
- The patent's scope has been maintained through annual maintenance fees without re-examinations or litigations.
Implications for R&D and Licensing
- The patent's expiration opens opportunities for generic development.
- The broad claims covering synthesis and use add to the patent's value as a blocking patent in the therapeutic class.
- The scope covers multiple formulations and methods, enabling flexible licensing strategies.
Key Takeaways
- The patent claims a specific heterocyclic compound, its salts, formulations, and therapeutic uses.
- The scope is comprehensive within the chemical structure and application space, but excludes structurally distinct compounds.
- A crowded patent landscape involves prior art on similar heterocyclic compounds and subsequent related filings.
- The patent's expiration in 2020 renders the core claims available for generic development, assuming no supplementary patents or exclusivities.
FAQs
1. What is the primary chemical structure claimed in US Patent 6,962,151?
It claims a heterocyclic compound with specific substituents at defined positions, including stereochemical configurations important for activity.
2. Are there any notable limitations to the patent claims?
Yes. The patent excludes compounds lacking the specific heterocyclic core or different substituents and does not claim unrelated chemical structures or therapeutic areas outside those specified.
3. How does the patent landscape look surrounding this patent?
Multiple related patents exist, including filings in Europe, Japan, and other jurisdictions. The landscape involves prior art with similar heterocyclic compounds and ongoing improvements.
4. Has the patent been challenged or litigated?
There are no publicly reported litigations or re-examinations, and the patent remains in good standing until expiration in 2020.
5. What opportunities exist now the patent has expired?
Generic manufacturers can now manufacture and market equivalents of the claimed compound and formulations, subject to regulatory approval.
References:
- United States Patent and Trademark Office. (2005). US Patent 6,962,151.
- European Patent Office. (n.d.). Related filings and applications.
- Scientific literature describing heterocyclic compounds and their activity (various publications).
- Patent databases for citation analysis (e.g., Lens.org).
- Regulatory filings and legal status reports (FDA, EPO).
